Literature DB >> 30003325

Incidentally detected pancreatic neuroendocrine microadenoma with lymph node metastasis.

Jeong-Hwa Kwon1, Hyoung Jung Kim2, Do Hyun Park3, Young-Joo Lee4, Christopher M Heaphy5, Günter Klöppel6, Ralph H Hruban7, Seung-Mo Hong8.   

Abstract

Pancreatic neuroendocrine microadenomas (NEMAs) are non-functioning neuroendocrine tumors < 0.5 cm with a low proliferation rate and are considered benign. We report on a pancreatic NEMA with lymph node metastasis. A male in his 70s had pylorus-preserving pancreaticoduodenectomy for a distal bile duct carcinoma, which was a 2.1 cm well-differentiated-infiltrating adenocarcinoma with invasion limited to the bile duct wall. An incidental separate 0.4 cm well-differentiated NEMA was found in the pancreatic head with metastatic well-differentiated neuroendocrine tumor in one peripancreatic lymph node. Both neuroendocrine tumors in the pancreatic head and in the lymph node were composed of nests of uniform neoplastic cells with a fine chromatin pattern. The Ki-67 labeling index of NEMA was 0.85%. The neoplastic neuroendocrine cells in both the pancreas and node were diffusely positive for synaptophysin, chromogranin, and insulin. Therefore, this unusual case provides an exception to the current classification system which regards NEMAs as benign lesions.

Entities:  

Keywords:  Lymph node; Malignant; Metastasis; Microadenoma; Neuroendocrine; Pancreas

Mesh:

Substances:

Year:  2018        PMID: 30003325     DOI: 10.1007/s00428-018-2407-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  12 in total

1.  Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases.

Authors:  W Kimura; A Kuroda; Y Morioka
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

2.  DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Authors:  Yuchen Jiao; Chanjuan Shi; Barish H Edil; Roeland F de Wilde; David S Klimstra; Anirban Maitra; Richard D Schulick; Laura H Tang; Christopher L Wolfgang; Michael A Choti; Victor E Velculescu; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos
Journal:  Science       Date:  2011-01-20       Impact factor: 47.728

3.  Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors.

Authors:  Joo Young Kim; Min-Sun Kim; Ki-Suk Kim; Ki-Byung Song; Seung Hun Lee; Dae Wook Hwang; Kyu-Pyo Kim; Hyoung Jung Kim; Eunsil Yu; Song Cheol Kim; Hyeung-Jin Jang; Seung-Mo Hong
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

4.  Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.

Authors:  Joo Young Kim; Jacqueline A Brosnan-Cashman; Soyeon An; Sung Joo Kim; Ki-Byung Song; Min-Sun Kim; Mi-Ju Kim; Dae Wook Hwang; Alan K Meeker; Eunsil Yu; Song Cheol Kim; Ralph H Hruban; Christopher M Heaphy; Seung-Mo Hong
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

5.  Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases.

Authors:  Epameinondas Dogeas; Georgios Karagkounis; Christopher M Heaphy; Kenzo Hirose; Timothy M Pawlik; Christopher L Wolfgang; Alan Meeker; Ralph H Hruban; John L Cameron; Michael A Choti
Journal:  J Am Coll Surg       Date:  2014-01-10       Impact factor: 6.113

6.  Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.

Authors:  Wenzel M Hackeng; Lodewijk A A Brosens; Katherine E Poruk; Michaël Noë; Waki Hosoda; Justin S Poling; Anthony Rizzo; Martha Campbell-Thompson; Mark A Atkinson; Björn Konukiewitz; Günter Klöppel; Christopher M Heaphy; Alan K Meeker; Laura D Wood
Journal:  Hum Pathol       Date:  2016-06-21       Impact factor: 3.466

7.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

8.  Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor.

Authors:  Martin Anlauf; Tetsuji Enosawa; Tobias Henopp; Anja Schmitt; Oliver Gimm; Michael Brauckhoff; Henning Dralle; Anette Musil; Steffen Hauptmann; Aurel Perren; Günter Klöppel
Journal:  Am J Surg Pathol       Date:  2008-07       Impact factor: 6.394

9.  Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.

Authors:  Ilaria Marinoni; Anja Schmitt Kurrer; Erik Vassella; Matthias Dettmer; Thomas Rudolph; Vanessa Banz; Fabio Hunger; Silvan Pasquinelli; Ernst-Jan Speel; Aurel Perren
Journal:  Gastroenterology       Date:  2013-10-19       Impact factor: 22.682

10.  Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.

Authors:  Roeland F de Wilde; Christopher M Heaphy; Anirban Maitra; Alan K Meeker; Barish H Edil; Christopher L Wolfgang; Trevor A Ellison; Richard D Schulick; I Quintus Molenaar; Gerlof D Valk; Menno R Vriens; Inne H M Borel Rinkes; G Johan A Offerhaus; Ralph H Hruban; Karen E Matsukuma
Journal:  Mod Pathol       Date:  2012-05-11       Impact factor: 7.842

View more
  2 in total

1.  Case Report: A Difficult-to-Diagnose Case of Hyperinsulinemic Hypoglycemia Surgically Treated After Developing Acute Pancreatitis.

Authors:  Chisa Inoue; Kota Nishihama; Aoi Hayasaki; Yuko Okano; Akinobu Hayashi; Kazuhito Eguchi; Mei Uemura; Toshinari Suzuki; Taro Yasuma; Takeshi Inoue; Tohru Yorifuji; Shugo Mizuno; Esteban C Gabazza; Yutaka Yano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-27       Impact factor: 5.555

Review 2.  Classification of neuroendocrine neoplasms: lights and shadows.

Authors:  Stefano La Rosa; Silvia Uccella
Journal:  Rev Endocr Metab Disord       Date:  2020-11-09       Impact factor: 9.306

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.